A Phase 1 Study of SP-02L in Relapsed or Refractory Patients With Peripheral T-cell Lymphoma (PTCL)
The purpose of this study is to evaluate the safety and tolerability of SP-02L monotherapy in Japanese patients with relapsed or refractory Peripheral T-cell Lymphoma (PTCL).
Peripheral T-cell Lymphoma
DRUG: SP-02L (darinaparsin for injection)|DRUG: SP-02L (darinaparsin for injection)|DRUG: SP-02L (darinaparsin for injection)
Incidence of dose-limiting toxicity and adverse events, 12 or 16 weeks
Tumor response (overall response), 2 and 4 cycles|Plasma concentration-time profile, Cmax, Area under Curve, tmax, t1/2, Clearance and Volume of distribution, 0, 0.5, 1, 2, 4, 8 hours post-dose on Day 1 and 5, and 0 hour on Day 2, 3, 4, 6, 8 and 15
The purpose of this study is to evaluate the safety and tolerability of SP-02L monotherapy in Japanese patients with relapsed or refractory Peripheral T-cell Lymphoma (PTCL).